Rafivirumab, formerly referred to as CR57, embodies a promising therapeutic designed for vascular endothelial proliferation factor receptor 2 , VEGFR2. Its path from preclinical identification involved a https://rafivirumab-cr57086930.aboutyoublog.com/profile